ertapenem has been researched along with ro13-9904 in 45 studies
| Studies (ertapenem) | Trials (ertapenem) | Recent Studies (post-2010) (ertapenem) | Studies (ro13-9904) | Trials (ro13-9904) | Recent Studies (post-2010) (ro13-9904) |
|---|---|---|---|---|---|
| 850 | 89 | 485 | 6,815 | 798 | 2,755 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (51.11) | 29.6817 |
| 2010's | 13 (28.89) | 24.3611 |
| 2020's | 9 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caballero-Lopez, J; Carides, A; Friedland, IR; Ortiz-Ruiz, G; Woods, GL | 1 |
| Friedland, I; Jiang, Q; Legua, P; Lema, J; Moll, J; Woods, G | 1 |
| Cajigas, J; Gesser, RM; Imbeault, D; Jasovich, A; Jiang, Q; Jimenez-Cruz, F; Woods, GL | 1 |
| Burdmann, EA; Gesser, RM; Jiang, Q; Reyna, OG; Tomera, KM; Wimmer, WM; Woods, GL | 1 |
| Adeyi, B; Fernandez, A; Geib, J; Hassett, JM; Teppler, H; Woods, GL; Yellin, AE | 1 |
| Friedland, I; Majumdar, A; Mixson, LA; Motyl, M; Woods, GL | 1 |
| Cambronero-Hernandez, E; Carides, A; Isaacs, R; Oliveria, T; Rohlf, J; Simon, S; Vetter, N | 1 |
| Gesser, RM; McCarroll, K; Teppler, H; Woods, GL | 1 |
| Gunderson, B; Hermsen, ED; Hovde, LB; Ibrahim, KH; Rotschafer, JC; Rotschafer, SE | 1 |
| Acosta, F; Cottagnoud, M; Cottagnoud, P; Pfister, M; Täuber, MG | 1 |
| Friedland, IR; Isaacs, RD; McCarroll, KA; Woods, GL | 1 |
| Carides, A; Friedland, I; Isaacs, R; Ortiz-Ruiz, G; Vetter, N; Woods, GL | 1 |
| Gesser, RM; Jiang, Q; Wells, WG; Woods, GL | 1 |
| Friedland, IR; Gesser, RM; Herman, G; Isaacs, R; Meibohm, A; Mistry, G; Teppler, H; Woods, GL | 1 |
| DiNubile, MJ; Friedland, IR; McCarroll, KA; Woods, GL | 1 |
| Bulitta, J; Burkhardt, O; De Roux, A; Kruse, G; Kurowski, M; Lode, H; Nord, CE; Pletz, MW; Rau, M | 1 |
| Chan, CY; Dinubile, MJ; Friedland, I; Giezek, H; Motyl, MR; Quinn, JP; Shivaprakash, M; Weinstein, RA | 1 |
| Donskey, CJ; Pultz, NJ; Stiefel, U | 1 |
| Borbone, S; Cascone, C; Mezzatesta, ML; Santagati, M; Stefani, S | 1 |
| Brunner, M; Burkhardt, O; Derendorf, H; Lobmeyer, MT; Röck, K; Sahre, M; Schmidt, S | 1 |
| Arguedas, A; Blumer, J; Botet, FA; Cespedes, J; Gesser, R; Snyder, T; Wang, J; West, J; Wimmer, W; Yogev, R | 1 |
| Chang, KT; Ledesma, KR; Quinn, JP; Tam, VH; Wang, TY | 1 |
| García, E; García, FJ; García, JE; García, MB; García, MI; González, B; Lozano, FS | 1 |
| Gómez del Valle, C; Matía, M; Pérez-Calvo, JI; Torralba, MÁ | 1 |
| Chau, F; Fantin, B; Le, P; Lefort, A; Lepeule, R; Massias, L; Nucci, A; Ruppé, E | 1 |
| Golparian, D; Lahra, MM; Limnios, A; Ohnishi, M; Tapsall, JW; Unemo, M; Whiley, D | 1 |
| Chung, MH; Kim, HY; Kim, JY; Kim, MJ; Lee, JS; Lee, MS; Park, DW; Park, YS; Peck, KR; Yeom, JS | 1 |
| Bai, N; Cai, Y; Liang, B; Liu, Y; Sun, C; Wang, J; Wang, R; Zhang, L | 1 |
| Kees, F; Kees, MG; Kratzer, A; Liebchen, U; Schleibinger, M | 1 |
| Caldwell, N; Cao, YK; Dai, WM; Leng, XS; Paschke, A; Qiu, HZ; Shen, JF; Wang, J; Zhao, YJ; Zhu, WH | 1 |
| Chang, FY; Chiu, CH; Lin, DY; Lin, HA; Lin, HC; Lin, JC; Wang, JX; Yang, YS; Yeh, KM | 1 |
| Bettoli, V; Join-Lambert, O; Nassif, A | 1 |
| Child, J; Crombleholme, T; Hurst, AL; Olson, D; Parker, SK; Pyle, L; Ranade, D; Somme, S; Stamatoiu, A | 1 |
| Basuino, L; Chambers, HF; Choo, EJ; Hamilton, SM; Moise, P | 1 |
| Di Maggio, T; Docquier, JD; Landini, G; Pallecchi, L; Rossolini, GM; Sergio, F | 1 |
| Barker, L; Beck, C; Cole, MJ; Cook, C; Eyre, DW; Fifer, H; Gardiner, D; Gobin, M; Horner, P; Irish, C; Mohammed, H; Nathan, B; Phin, N; Pitt, R; Sanderson, N; Saunders, J; Sedgwick, J; Street, T; Town, K; Turbitt, D | 1 |
| Baldolli, A; Colin, E; Saint-Lorant, G; Verdon, R | 1 |
| Abdul-Aziz, MH; Ahern, B; Dhanani, JA; Jackson, K; Lipman, J; Lupinsky, L; Roberts, JA; Wallis, SC | 1 |
| Chen, YH; Chen, YS; Cheng, SH; Hsueh, PR; Ko, WC; Lee, CM; Lee, WS; Lee, YL; Lin, CN; Lin, CY; Liu, CP; Lu, MC; Lu, PL; Shao, PL; Sheng, WH; Shi, ZY; Tang, HJ; Tsai, YT; Tseng, SH; Wang, FD; Wang, LS; Wu, TS; Yen, MY | 1 |
| Allen, GP; Deao, KM; Hill, SA; Schipelliti, SM; Tran, T | 1 |
| Boyd, A; de Korne-Elenbaas, J; de Laat, M; de Vries, HJC; Heijman, T; Jongen, VW; Schim van der Loeff, MF; van Dam, AP; Wind, CM | 1 |
| Daneman, N; Elligsen, M; Katz, K; Lam, PW; Lo, J; MacFadden, D; Teitelbaum, D; Vermeiren, C | 1 |
| Cusumano, JA; Daffinee, KE; Desbonnet, C; García-Solache, M; LaPlante, KL; Piehl, EC; Rice, LB | 1 |
| Abdulhemid Said, L; Muhsin, EA; Sajid Al-Jubori, S | 1 |
| Brouqui, P; Cassir, N; Guilhaumou, R; Jumpertz, M; Lagier, JC; Million, M; Parola, P | 1 |
5 review(s) available for ertapenem and ro13-9904
| Article | Year |
|---|---|
Safety and tolerability of ertapenem.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; beta-Lactams; Ceftriaxone; Clinical Trials as Topic; Community-Acquired Infections; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Randomized Controlled Trials as Topic | 2004 |
Ertapenem versus ceftriaxone for the treatment of complicated infections: a meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Ertapenem; Humans; Intraabdominal Infections; Pneumonia; Randomized Controlled Trials as Topic; Urinary Tract Infections | 2014 |
Antibiotic Treatment of Hidradenitis Suppurativa.
Topics: Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Clindamycin; Drug Therapy, Combination; Ertapenem; Fluoroquinolones; Hidradenitis Suppurativa; Humans; Imipenem; Maintenance Chemotherapy; Metronidazole; Moxifloxacin; Remission Induction; Rifampin | 2016 |
Subcutaneously administered antibiotics.
Topics: Age Factors; Anti-Bacterial Agents; Bacterial Infections; Ceftriaxone; Clinical Trials as Topic; Cohort Studies; Ertapenem; Humans; Infusions, Intravenous; Injections, Intravenous; Injections, Subcutaneous; Microbial Sensitivity Tests; Teicoplanin | 2020 |
Subcutaneously administered antibiotics: a review.
Topics: Anti-Bacterial Agents; Cefepime; Ceftriaxone; Ertapenem; Humans; Teicoplanin | 2022 |
16 trial(s) available for ertapenem and ro13-9904
| Article | Year |
|---|---|
A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Drug Tolerance; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2002 |
Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone.
Topics: Aged; Anesthetics, Local; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Cephalosporins; Double-Blind Method; Ertapenem; Female; Humans; Injections, Intramuscular; Lactams; Lidocaine; Male; Middle Aged; Prospective Studies; Respiratory Tract Infections; Skin Diseases, Infectious | 2002 |
A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults.
Topics: Administration, Oral; Adult; Age Factors; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Cephalosporins; Double-Blind Method; Ertapenem; Escherichia coli; Escherichia coli Infections; Humans; Infusions, Intravenous; Lactams; Prospective Studies; Treatment Outcome; Urinary Tract Infections | 2002 |
Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; beta-Lactams; Ceftriaxone; Cephalosporins; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Male; Prospective Studies; Urinary Tract Infections | 2002 |
Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults.
Topics: Abdomen; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; beta-Lactams; Ceftriaxone; Double-Blind Method; Drug Therapy, Combination; Ertapenem; Female; Humans; Injections, Intravenous; Lactams; Male; Metronidazole; Middle Aged | 2002 |
A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Community-Acquired Infections; Double-Blind Method; Ertapenem; Europe; Female; Hospitalization; Humans; Injections, Intramuscular; Injections, Intravenous; Lactams; Latin America; Male; Middle Aged; Pneumonia, Pneumococcal; Prospective Studies; Severity of Illness Index; Streptococcus pneumoniae; Treatment Outcome; United States | 2002 |
Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
Topics: Adult; Aged; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Enterobacteriaceae Infections; Ertapenem; Escherichia coli Infections; Humans; Lactams; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2003 |
Ertapenem therapy for community-acquired pneumonia in the elderly.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Community-Acquired Infections; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Logistic Models; Male; Odds Ratio; Pneumonia, Pneumococcal; Retrospective Studies; Statistics, Nonparametric; Streptococcus pneumoniae; Treatment Outcome | 2003 |
Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Child; Child, Preschool; Community-Acquired Infections; Double-Blind Method; Ertapenem; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Lactams; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2004 |
Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Double-Blind Method; Drug Administration Schedule; Ertapenem; Female; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Lactams; Male; Middle Aged; Multicenter Studies as Topic; Pyelonephritis; Randomized Controlled Trials as Topic; Treatment Outcome; Urinary Tract Infections | 2004 |
Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers.
Topics: Adult; beta-Lactams; Ceftriaxone; Cephalosporins; Cross-Over Studies; Double-Blind Method; Ertapenem; Feces; Female; Humans; Intestines; Lactams; Male; Mass Spectrometry; Sex Characteristics | 2004 |
Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Carrier State; Ceftriaxone; Digestive System Surgical Procedures; Drug Resistance, Bacterial; Drug Therapy, Combination; Ertapenem; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intestines; Lactams; Male; Metronidazole; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2005 |
Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Child; Child, Preschool; Community-Acquired Infections; Double-Blind Method; Ertapenem; Female; Humans; Infant; Male; Molecular Sequence Data; Pneumonia, Bacterial; Skin Diseases, Bacterial; Soft Tissue Infections; Urinary Tract Infections | 2009 |
Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in Korean adults: a randomized, double-blind, multicenter trial.
Topics: Acute Disease; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Double-Blind Method; Ertapenem; Humans; Odds Ratio; Pyelonephritis; Republic of Korea; Risk Factors; Urinary Tract Infections | 2012 |
Ertapenem prophylaxis of surgical site infections in elective colorectal surgery in China: a multicentre, randomized, double-blind, active-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; beta-Lactams; Ceftriaxone; China; Colorectal Surgery; Double-Blind Method; Ertapenem; Female; Humans; Infusions, Intravenous; Laparotomy; Male; Metronidazole; Middle Aged; Placebos; Surgical Wound Infection; Treatment Outcome; Young Adult | 2014 |
Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial.
Topics: Adult; Anti-Bacterial Agents; Ceftriaxone; Ertapenem; Fosfomycin; Gentamicins; Gonorrhea; Humans; Neisseria gonorrhoeae; Treatment Outcome | 2022 |
24 other study(ies) available for ertapenem and ro13-9904
| Article | Year |
|---|---|
In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Ceftriaxone; Community-Acquired Infections; Drug Resistance, Microbial; Drug Therapy, Combination; Enterobacteriaceae; Ertapenem; Haemophilus influenzae; Humans; Lactams; Microbial Sensitivity Tests; Moraxella catarrhalis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pyogenes | 2002 |
Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Drug Resistance, Microbial; Ertapenem; Humans; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Mutation; Pharmacogenetics; Probability; Sensitivity and Specificity; Streptococcus pneumoniae; Thienamycins | 2003 |
Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Disease Models, Animal; Ertapenem; Lactams; Meningitis, Pneumococcal; Penicillin Resistance; Rabbits; Streptococcus pneumoniae; Vancomycin | 2003 |
Ertapenem as initial antimicrobial monotherapy for patients with chronic obstructive pulmonary disease hospitalized with typical community-acquired pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Community-Acquired Infections; Drug Therapy, Combination; Enterobacteriaceae; Ertapenem; Female; Haemophilus influenzae; Hospitalization; Humans; Injections, Intravenous; Lactams; Male; Middle Aged; Pneumonia, Bacterial; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Streptococcus pneumoniae; Treatment Outcome | 2004 |
Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
Topics: Animals; beta-Lactams; Carbapenems; Ceftriaxone; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Enterococcus; Ertapenem; Female; Imipenem; Intestines; Klebsiella pneumoniae; Mice; Piperacillin; Sodium Chloride; Time Factors; Vancomycin Resistance | 2007 |
Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Topics: Abdomen; Anti-Bacterial Agents; Bacterial Infections; Bacteroides fragilis; beta-Lactams; Ceftazidime; Ceftriaxone; Digestive System Diseases; Enterobacter cloacae; Enterococcus faecalis; Ertapenem; Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Klebsiella; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus mirabilis; Staphylococcus aureus; Time Factors | 2006 |
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Blood Proteins; Cattle; Ceftriaxone; Drug Discovery; Ertapenem; Escherichia coli; Humans; In Vitro Techniques; Models, Biological; Protein Binding; Serum Albumin; Serum Albumin, Bovine; Streptococcus pneumoniae | 2008 |
Killing of Escherichia coli by beta-lactams at different inocula.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Ceftriaxone; Colony Count, Microbial; Ertapenem; Escherichia coli; Humans; Microbial Viability; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors | 2009 |
[Activity of Ertapenem and Ceftriaxone in the eradication of Salmonella in a model of experimental peritonitis in mice].
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Dose-Response Relationship, Drug; Ertapenem; Male; Mice; Peritonitis; Salmonella enterica; Salmonella Infections | 2009 |
[Treatment of community-acquired pneumonia in adults: ertapenem versus cefditoren?].
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Ertapenem; Humans; Ofloxacin; Pneumonia, Bacterial | 2010 |
Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; beta-Lactams; Carbapenems; Cefoxitin; Ceftriaxone; Conjugation, Genetic; Disease Models, Animal; Drug Administration Schedule; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Kidney; Mice; Microbial Sensitivity Tests; Mutation Rate; Plasmids; Urinary Bladder; Urinary Tract Infections | 2012 |
In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?
Topics: Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Drug Resistance, Bacterial; Ertapenem; Gonorrhea; Humans; Microbial Sensitivity Tests; Neisseria gonorrhoeae | 2012 |
Determination of free vancomycin, ceftriaxone, cefazolin and ertapenem in plasma by ultrafiltration: impact of experimental conditions.
Topics: beta-Lactams; Cefazolin; Ceftriaxone; Drug Stability; Ertapenem; Humans; Protein Binding; Ultrafiltration; Vancomycin | 2014 |
Comparison of the effectiveness and antibiotic cost among ceftriaxone, ertapenem, and levofloxacin in treatment of community-acquired complicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Community-Acquired Infections; Costs and Cost Analysis; Ertapenem; Escherichia coli; Female; Humans; Length of Stay; Levofloxacin; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Urinary Tract Infections; Young Adult | 2016 |
Once-Daily Ceftriaxone Plus Metronidazole Versus Ertapenem and/or Cefoxitin for Pediatric Appendicitis.
Topics: Abdominal Abscess; Adolescent; Appendectomy; Appendicitis; beta-Lactams; Cefoxitin; Ceftriaxone; Child; Child, Preschool; Cost Savings; Cost-Benefit Analysis; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Ertapenem; Female; Humans; Infant; Laparoscopy; Male; Metronidazole; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Daptomycin-β-Lactam Combinations in a Rabbit Model of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Endocarditis.
Topics: Animals; beta-Lactams; Ceftriaxone; Cephalosporins; Daptomycin; Endocarditis, Bacterial; Ertapenem; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Rabbits | 2016 |
Effect of High N-Acetylcysteine Concentrations on Antibiotic Activity against a Large Collection of Respiratory Pathogens.
Topics: Acetylcysteine; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Drug Combinations; Drug Interactions; Enterobacter cloacae; Ertapenem; Escherichia coli; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillins; Pseudomonas aeruginosa; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae; Streptococcus pyogenes; Thienamycins | 2016 |
Detection in the United Kingdom of the
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Drug Resistance, Bacterial; Ertapenem; Female; Gonorrhea; Humans; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Polymorphism, Single Nucleotide; Treatment Outcome; United Kingdom; Whole Genome Sequencing | 2019 |
Comparative Plasma Pharmacokinetics of Ceftriaxone and Ertapenem in Normoalbuminemia, Hypoalbuminemia, and Albumin Replacement in a Sheep Model.
Topics: Animals; Anti-Bacterial Agents; Ceftriaxone; Ertapenem; Hypoalbuminemia; Pharmaceutical Preparations; Prospective Studies; Sheep | 2020 |
Nationwide surveillance of antimicrobial resistance in invasive isolates of Streptococcus pneumoniae in Taiwan from 2017 to 2019.
Topics: Aged; Anti-Bacterial Agents; Ceftriaxone; Doripenem; Drug Resistance, Bacterial; Ertapenem; Humans; Levofloxacin; Linezolid; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Penicillins; Pneumococcal Infections; Streptococcus pneumoniae; Taiwan; Vancomycin | 2022 |
In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Ciprofloxacin; Doxycycline; Drug Resistance, Multiple, Bacterial; Ertapenem; Gentamicins; Gonorrhea; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Neisseria gonorrhoeae | 2021 |
Introducing the Escalation Antibiogram: A Simple Tool to Inform Changes in Empiric Antimicrobials in the Nonresponding Patient.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Ceftriaxone; Ciprofloxacin; Ertapenem; Gentamicins; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Tobramycin; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an
Topics: Adenosine Monophosphate; Ampicillin; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Drug Synergism; Enterococcus faecalis; Ertapenem; Humans; Meropenem; Microbial Sensitivity Tests | 2022 |
Prevalence of Efflux Pump and Porin-Related Antimicrobial Resistance in Clinical
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefazolin; Cefepime; Cefoxitin; Ceftazidime; Ceftriaxone; Cephalosporins; Drug Resistance, Bacterial; Ertapenem; Humans; Imipenem; Iraq; Klebsiella pneumoniae; Microbial Sensitivity Tests; Porins; Prevalence | 2022 |